TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00625924

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States - Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
Study: NCT03514186

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech and Language Therapy
Description: Includes:~* one hour of individual therapy using a multimodality treatment called Verb Network Strengthening Treatment (VNeST) that simultaneously targets semantics (word retrieval) and syntax (sentence construction);~* one hour of constraint induced language therapy (CILT) where participants are paired and practice requesting and providing specific information using only spoken language;~* one hour in the computer lab working on programs called Oral Reading for Language in Aphasia (ORLA) and AphasiaScripts; and~* one hour in a conversation group that emphasizes multimodality communication

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech and Language Therapy
Description: Includes:~* one hour of individual therapy using a multimodality treatment called Verb Network Strengthening Treatment (VNeST) that simultaneously targets semantics (word retrieval) and syntax (sentence construction);~* one hour of constraint induced language therapy (CILT) where participants are paired and practice requesting and providing specific information using only spoken language;~* one hour in the computer lab working on programs called Oral Reading for Language in Aphasia (ORLA) and AphasiaScripts; and~* one hour in a conversation group that emphasizes multimodality communication
Study: NCT03806335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infiltration
Description: The infiltration will be performed by the anesthetist using a 25G- 3.5cm curved needle. A total of 2.5 ml of local anesthetic mixture will be used for each tonsil. The mixture will contain: 10 ml xylocaine 2% an d10 ml bupivacaine 0.5%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 2.5 ml normal saline in each tonsil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: All patients will receive general anesthesia prior to infiltration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General anesthesia
Description: All patients will receive general anesthesia prior to infiltration
Study: NCT02249117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIWH 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04429841

Intervention type: PROCEDURE
Intervention: Radical gastrectomy with D1 lymphadenectomy

Intervention type: PROCEDURE
Intervention: Radical gastrectomy with D2 lymphadenectomy
Study: NCT01657526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A)
Description: Administered intramuscularly (IM) in the deltoid region of non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A)
Description: 2 doses administered IM in the deltoid region of non-dominant arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: 2 doses administered IM in the deltoid region of non-dominant arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: 2 doses administered IM in the deltoid region of non-dominant arm
Study: NCT05491720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Patients will receive 10 sessions of 20 minutes of 1.5 mA electrical stimulation on consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo tablet (Galenus pharmaceutical company)
Study: NCT03422848

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Increased daily water intake with 1.5 L of water on top of habitual water intake.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: general life style advice
Description: oral and written advice on diet and physical activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: general life style advice
Description: oral and written advice on diet and physical activity
Study: NCT03141684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and urine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and urine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT05491720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive placebo tablet (Galenus pharmaceutical company)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: Patients will receive 10 sessions of 20 minutes of sham electrical stimulation on consecutive days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham transcranial direct current stimulation
Description: Patients will receive 10 sessions of 20 minutes of sham electrical stimulation on consecutive days
Study: NCT00981201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Months 1-3:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Months 1-3:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Months 4-6:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Months 4-6:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Months 1-3:~By mouth twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Months 1-3:~By mouth twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Months 4-6:~By mouth twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Months 4-6:~By mouth twice daily.
Study: NCT02439060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acellular Cadaveric Dermal Matrix
Description: Undergo intraperitoneal prophylactic mesh placement
Study: NCT04282642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Participants (n=20) provided game console with cognitive training games and activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WLC (Waitlist Control)
Description: Participants (n=20) will receive the cognitive training intervention later, following week 8 assessments.
Study: NCT02758769

Intervention type: BIOLOGICAL
Intervention: ORENCIA Subcutaneous Injection
Study: NCT03802396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN-105
Description: Three doses of CN-105 will be used in three successive cohorts of 50 patients each.~0.1 mg/kg (cohort 1), 0.5 mg/kg (cohort 2), 1 mg/kg (cohort 3)~The study drug will be administered by IV every 6 hours, beginning 1 hour prior to surgery, until postoperative day 3 or hospital discharge, whichever occurs first, up to a maximum of 13 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo intravenously every 6 hours, beginning 1 hour prior to surgery, until postoperative day 3 or hospital discharge, whichever occurs first, up to a maximum of 13 doses, identical to those receiving the study drug.
Study: NCT06750770

Intervention type: DIAGNOSTIC_TEST
Intervention: KDIGO CRITERIA
Description: 2012 KDIGO DIAGNOSTIC CRITERIA

Intervention type: DIAGNOSTIC_TEST
Intervention: KDIGO CRITERIA
Description: 2012 KDIGO DIAGNOSTIC CRITERIA
Study: NCT00543127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral Anastrozole per day during 5 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1 mg oral Anastrozole per day during 5 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg oral Anastrozole per day during 5 years.
Study: NCT02618941

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFFITOPE® PD01A
Description: s.c. injection
Study: NCT00226356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplements of L-methionine, betaine and folate
Study: NCT00163293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: Ciclesonide metered-dose inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: Ciclesonide metered-dose inhaler
Study: NCT01199965

Intervention type: DRUG
Group type: OTHER
Intervention: MAP0004
Description: 1.0mg MAP0004 via inhalation at Visit 2 or 3 as per protocol

Intervention type: DRUG
Group type: OTHER
Intervention: MAP0004
Description: 1.0mg MAP0004 via inhalation at Visit 2 or 3 as per protocol
Study: NCT00163293

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ciclesonide placebo-matching metered-dose inhaler
Study: NCT03834740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib administered orally in 5 daily doses prior to resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib administered orally in 5 daily doses prior to resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib administered orally in 5 daily doses prior to resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus administered orally in 5 daily doses prior to resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus administered orally in 5 daily doses prior to resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus administered orally in 5 daily doses prior to resection
Study: NCT01107886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 5 mg or 2.5 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03506360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01580787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance Training with Nintendo Wii Fit
Description: The participants of the study trained 10 balance games during 14 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Patients of the control group was trained with balance exercises.
Study: NCT03253172

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium Chloride
Description: Two potassium supplements with varying anions.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium Citrate
Description: Potassium Citrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01199965

Intervention type: DRUG
Group type: OTHER
Intervention: IV DHE
Description: IV DHE administered at Visit 2 or 3 as per protocol
Study: NCT04360941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Highly selective oral inhibitor of CDK4 and CDK6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Fully human IgG1 monoclonal antibody (mAb) binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.
Study: NCT02242266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium low dose
Description: inhalation powder, hard PE capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium medium dose
Description: inhalation powder, hard PE capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spiriva® HandiHaler® high dose
Description: Tiotropium inhalation powder, hard gelatine capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo via the blue HandiHaler®
Description: oral inhalation via the blue HandiHaler®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo via the blue HandiHaler®
Description: oral inhalation via the blue HandiHaler®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo via the grey HandiHaler®
Description: oral inhalation via the grey HandiHaler®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo via the grey HandiHaler®
Description: oral inhalation via the grey HandiHaler®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo via the grey HandiHaler®
Description: oral inhalation via the grey HandiHaler®
Study: NCT00499499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7107
Description: E7107 will be administered as an intravenous infusion over 30 minutes at a starting dose of 0.6 mg/m\^2 to the first cohort of patients. The same dose will be given on Days 1 and 8 of a 21-day cycle. Dose escalation will not occur until the maximum tolerated dose is reached. The selection of subsequent dose levels will be performed according to an accelerated design.
Study: NCT02124525

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetylcysteine
Description: N-acetylcysteine 3000mg a day for 12 weeks versus Placebo for 12 weeks
Study: NCT00921739

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Esophageal sparing IMRT
Description: 6 fractions/week of 2Gy each for 29 fx (58 Gy), 31 fx (62 Gy), 33 fx (66 Gy), 35 fx (70 Gy), or 37 fx (74 Gy).
Study: NCT03525041

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: CABG will be performed using standard surgical techniques. All procedures will be performed with cardiopulmonary bypass(CPB). Saphenous vein(SV)will be used as conduit but harvesting methods will not be prescribed, and utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, judging by the surgical investigator.
Study: NCT02972671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiStent (MT005) Coronary Artery Stent
Description: Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience Coronary Artery Stent
Description: Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
Study: NCT00417508

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sip feeding
Description: Daily supplement with sip feeding, 2 packages(each package containing 200 ml,20 g protein and 300 kcal)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Advice
Description: The patients will receive ordinary dietary advice with a recommendation of four meals per day or similar dietary advice and no daily sip feeding supplements.
Study: NCT00489138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: 1g a day by drip of 30 min
Study: NCT03137537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: lower heart rate in heart failure patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Procedure prescribed to compare the active effect of a medicine.
Study: NCT03525041

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: CABG will be performed using standard surgical techniques. All procedures will be performed with cardiopulmonary bypass(CPB). Saphenous vein(SV)will be used as conduit but harvesting methods will not be prescribed, and utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, judging by the surgical investigator.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mitral valve annuloplasty
Description: Surgical techniques for mitral valve annuloplasty may need to be adjusted at the discretion of the surgeon, as based on intra-operative findings that may not be previously recognized in the pre-operative evaluation.
Study: NCT03011710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProVari v2.5 (E-cigarette)
Description: An electronic cigarette or e-cigarette is a handheld electronic device that vaporizes a flavored liquid. The user inhales the vapor. The fluid in the e-cigarette, called e-liquid, is usually made of nicotine, propylene glycol, glycerine, and flavorings.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProVari v2.5 (E-cigarette)
Description: An electronic cigarette or e-cigarette is a handheld electronic device that vaporizes a flavored liquid. The user inhales the vapor. The fluid in the e-cigarette, called e-liquid, is usually made of nicotine, propylene glycol, glycerine, and flavorings.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Marlboro Gold (Conventional cigarette)
Description: Conventional cigarette

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cigarette tip
Description: Placebo device
Study: NCT02352129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CMR using T1 mapping technique
Description: the level of myocardial fibrosis for patient suffering of cardiomyopathy dilated will be quantified using CMR T1 mapping technique

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CMR using T1 mapping technique
Description: the level of myocardial fibrosis for patient suffering of cardiomyopathy dilated will be quantified using CMR T1 mapping technique
Study: NCT02269306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphen citrate
Description: The study was carried out on 150 patients with PCOS. Initial clomiphen citrate (CC) doses were 50 mg daily for 5 days starting on cycle day 3. In the case of an absent response, doses were increased to 100 and 150 mg daily in subsequent cycles. First ovulation with CC was used as the end point.
Study: NCT02530684

Intervention type: OTHER
Intervention: insole
Description: Insoles available on the market without prescription

Intervention type: OTHER
Intervention: insole
Description: Insoles available on the market without prescription
Study: NCT01848730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNV2197944

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02564796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa and Iron
Description: Patients in the treatment group will receive weekly EPO injections and iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization) They will be followed for 14 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iron
Description: Patients in the treatment group will not receive any extra intervention outside of standard of care. They will receive iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization). They will be followed for 14 weeks.
Study: NCT01545804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: All enrolled patients will receive Lenalidomide, 25 mg orally daily, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
Study: NCT04089618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBLM
Description: Complex 8 week Mind-Body program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBLM
Description: Complex 8 week Mind-Body program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBLM
Description: Complex 8 week Mind-Body program.
Study: NCT00946751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam Tablets, 750 mg (Sandoz Inc.)
Study: NCT04395404

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Patients with unilateral ASS, with and without the prosthesis in situ, are analysed by 3D- magnetic resonance imaging (MRI) with 64 channel head coil using T1 and T2 weighted, DIXON/ IDEAL, and T2 inversion recovery sequences.